Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants
Preliminary immunological evaluation showed that antibodies from Castle1-immunised animals possessed haemagglutination inhibition activity and interacted with NDV of genotypes I and VII, which makes Castle1 a promising antigen for the further development of a vaccine for preventing ongoing and incoming NDV outbreaks.